|
- The state of cell and gene therapy in 2023: Molecular Therapy
In early 2023, there were more than 100 different approved gene, cell, and RNA therapies throughout the world, with over 3,700 more in clinical and preclinical development This review comprehensively captures the landscape for such advanced therapies, including the different genetic technologies used and diseases targeted in clinical trials
- A new age of precision gene therapy - The Lancet
Gene therapy has become a clinical reality as market-approved advanced therapy medicinal products for the treatment of distinct monogenetic diseases and B-cell malignancies This Therapeutic Review aims to explain how progress in genome editing technologies offers the possibility to expand both therapeutic options and the types of diseases that will become treatable To frame these impressive
- Advancements in gene therapy for human diseases: Trend of current . . .
Gene therapy is a rapidly evolving field with significant potential for treating different types of human diseases The trend of current clinical trials suggests that there is growing interest and investment in exploring gene therapy as a viable treatment option
- Gene Therapy: A Comprehensive Review of Mechanisms, Applications, Risks . . .
Abstract Gene therapy, a revolutionary approach to treating diseases by modifying a patient's genes, has rapidly evolved from theoretical possibility to clinical reality This report provides a comprehensive overview of gene therapy, encompassing its underlying mechanisms, various delivery methods,
- The Future is Now: Cell and Gene Therapy Innovation, Challenges, and . . .
The Future is Now: Cell and Gene Therapy Innovation, Challenges, and Perspectives Cell and gene therapies have the potential to revolutionize treatment of a wide range of diseases With six new therapies approved in 2022, including the first allogeneic T-cell therapy, and at least as many slated for approval this year, the sector is poised for rapid growth This innovation comes with
- Year In Review: Gene Therapies Make a Big Splash in 2023
Gene therapies are changing the way we treat diseases by targeting the cause of a disease directly at the DNA level, rather than mitigating symptoms, and creating long-lasting change in the body 2023 was a pivotal year in this field with several gene therapies approved to help patients and families battling Duchenne muscular dystrophy, amyotrophic lateral sclerosis, hematologic malignancies
- Piping Hot: A look at the state of cell, gene and RNA therapies in . . .
Innovation does not stop In 2022, the EMA approved Biomarin’s gene therapy Roctavian for patients suffering from severe haemophilia A and 2023 might see the first-ever approval of Vertex CRISPR Therapeutics’ exa-cel gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia 2 3
- Beacon | 2023 Gene Therapy Landscape Review
We are pleased to present our 2023 Gene Therapy Landscape Review Our comprehensive analysis provides valuable insights into the rapidly evolving field, empowering you to make informed decisions and stay ahead of the curve
|
|
|